

Circulation

Volume 136, Issue 6, 8 August 2017; Pages e137-e161
<https://doi.org/10.1161/CIR.0000000000000509>



ACC/AHA/HFSA FOCUSED UPDATE

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America

Clyde W. Yancy, MD, MSc, MACC, FAHA, FHFSA, Chair, Mariell Jessup, MD, FACC, FAHA, Vice Chair, Biykem Bozkurt, MD, PhD, FACC, FAHA, Javed Butler, MD, MBA, MPH, FACC, FAHA, Donald E. Casey, Jr, MD, MPH, MBA, FACC, Monica M. Colvin, MD, FAHA, Mark H. Drazner, MD, MSc, FACC, FAHA, FHFSA, Gerasimos S. Filippatos, MD, Gregg C. Fonarow, MD, FACC, FAHA, FHFSA, Michael M. Givertz, MD, FACC, FHFSA, Steven M. Hollenberg, MD, FACC, JoAnn Lindenfeld, MD, FACC, FAHA, FHFSA,



1. Introduction

The purpose of this focused update is to update the "2013 ACCF/AHA Guideline for the Management of Heart Failure"⁹ (2013 HF guideline) in areas in which new evidence has emerged since its publication. For this update and future heart failure (HF) guidelines, the Heart Failure Society of America (HFSA) has partnered with the ACC and AHA to provide coordinated guidance on the management of HF.

The scope of the focused update includes revision to the sections on biomarkers; new therapies indicated for stage C HF with reduced ejection fraction (HF/EF); updates on HF with preserved ejection fraction (HFpEF); new data on important comorbidities, including sleep apnea, anemia, and hypertension; and new insights into the prevention of HF.

This focused update represents the second part of a 2-stage publication; with the first part having been published as the "2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure,"¹⁰ which introduced guidance on new therapies, specifically for the use of an angiotensin receptor–neprilysin inhibitor (ARNI) (valsartan/sacubitril) and a sinoatrial node modulator (ivabradine). That focused update was published concurrently with the European Society of Cardiology's complete guideline, "2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure."¹¹

1.1. Methodology and Evidence Review

To identify key data that influence guideline recommendations, the Task Force and members of the 2013 HF guideline writing committee reviewed clinical trials that were reported at the

